Offer Update

AstraZeneca PLC
19 June 2007



(NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR
FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION)





          AstraZeneca Successfully Completes Acquisition of MedImmune



AstraZeneca PLC ('AstraZeneca') today announced that on June 18, 2007 it
completed its acquisition of MedImmune, Inc. ('MedImmune') pursuant to a
short-form merger in which a subsidiary of AstraZeneca was merged with and into
MedImmune with MedImmune continuing as the surviving corporation.  MedImmune is
accordingly now 100% owned by AstraZeneca.  AstraZeneca had previously announced
the acquisition of approximately 91.6% of MedImmune's outstanding common stock
pursuant to a cash tender offer.  In connection with the merger, all remaining
outstanding shares of MedImmune's common stock (other than any shares in respect
of which appraisal rights are validly exercised under Delaware law and any
shares owned by MedImmune, AstraZeneca or any of their subsidiaries), were
converted into the right to receive the same $58.00 cash per share, without
interest, that was paid in the tender offer.





                                     -Ends-

June 19 2007


AstraZeneca

Media Enquiries:
Steve Brown / Edel McCaffrey (London)                       [phone]/5034
Staffan Ternby (Sweden)                                            (8) 553 26107
Emily Denney (Wilmington)                                         [phone]

Analyst/Investor Enquiries:
Jonathan Hunt / Mina Blair / Karl Hard  (London)       [phone]/5084/5322
Staffan Ternby (Sweden)                                            (8) 553 26107
Ed Seage / Jorgen Winroth (US)                     [phone]/[phone]

Merrill Lynch (Financial Adviser to AstraZeneca)            [phone]
Richard Girling

Deutsche Bank (Joint Corporate Broker to AstraZeneca)       [phone]
Charlie Foreman

Goldman Sachs (Joint Corporate Broker to AstraZeneca)       [phone]
Phil Raper

MedImmune

Media Enquiries:
Jamie Lacey                                                         301-398-4035

Analyst/Investor Enquiries:
Pete Vozzo                                                          301-398-4358



Not for release, publication or distribution, in whole or in part, in, into or
from Australia, Canada or Japan




                      This information is provided by RNS
            The company news service from the London Stock Exchange